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Abstract
Background: Although pig-tailed macaques (Macaca nemestrina) have been used in AIDS research
for years, less is known about the early immunopathogenic events in this species, as compared to
rhesus macaques (Macaca mulatta). Similarly, the events in early infection are well-characterized for
simian immunodeficiency viruses (SIV), but less so for chimeric simian-human immunodeficiency
viruses (SHIV), although the latter have been widely used in HIV vaccine studies. Here, we report
the consequences of intrarectal infection with a CCR5-tropic clade C SHIV-1157ipd3N4 in pig-
tailed macaques.
Results: Plasma and cell-associated virus was detectable in peripheral blood and intestinal tissues
of all four pig-tailed macaques following intrarectal inoculation with SHIV-1157ipd3N4. We also
observed a rapid and irreversible loss of CD4+ T cells at multiple mucosal sites, resulting in a
marked decrease of CD4:CD8 T cell ratios 0.5–4 weeks after inoculation. This depletion targeted
subsets of CD4+ T cells expressing the CCR5 coreceptor and having a CD28-CD95+ effector
memory phenotype, consistent with the R5-tropism of SHIV-1157ipd3N4. All three animals that
were studied beyond the acute phase seroconverted as early as week 4, with two developing cross-
clade neutralizing antibody responses by week 24. These two animals also demonstrated persistent
plasma viremia for >48 weeks. One of these animals developed AIDS, as shown by peripheral blood
CD4+ T-cell depletion starting at 20 weeks post inoculation.
Conclusion: These findings indicate that SHIV-1157ipd3N4-induced pathogenesis in pig-tailed
macaques followed a similar course as SIV-infected rhesus macaques. Thus, R5 SHIV-C-infection of
pig-tailed macaques could provide a useful and relevant model for AIDS vaccine and pathogenesis
research.
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Background
The research of AIDS pathogenesis has been facilitated by
the use of Asian macaques known to develop AIDS-like
diseases from lentivirus infection, including rhesus (M.
mulatta), cynomolgus (M. fascicularis), and pig-tailed (M.
nemestrina) macaques [1-11]. Studies in rhesus macaques
have provided extensive insight into the biology of dis-
ease-susceptible animals to advance ongoing efforts
towards developing an effective human AIDS vaccine. On
the other hand, much less is known about the early events
after lentiviral infection in other macaque species, includ-
ing pig-tailed macaques.
The species/subspecies of macaques used in a study can be
a significant determinant of viral infectivity and disease
susceptibility. For example, in a comparative study of
Asian macaques infected intravenously with simian
immunodeficiency virus (SIV) or simian-human immun-
odeficiency virus (SHIV) strains, SIVmac251 or
SHIV89.6P, Reimann et al. found lower plasma viral
loads, higher levels of peripheral CD4+ T cells, and higher
survival rates in cynomolgus and Chinese rhesus, com-
pared to similarly infected Indian rhesus [12]. Interest-
ingly, ten Haaft et al. reported contrasting findings in
cynomolgus vs. Indian rhesus infected intravenously or
via select mucosal routes [13]. Their study showed that
while cynomolgus macaques had lower steady-state viral
loads after SIV infection, there was no such difference after
SHIV89.6P infection. Consistent with the Reimann et al.
report above, Ling et al. also showed a differential
response to lentiviral infection at the subspecies level.
Compared to their Indian counterparts, Chinese rhesus
infected with SIVmac239 had lower plasma viral loads in
acute infection, maintained lower setpoint plasma
viremia, and experienced less severe depletion of intesti-
nal CD4+ effector cells, all of which resulted in better clin-
ical outcomes [14]. However, Burdo et al. found that serial
passage of SIVmac128 in Chinese rhesus resulted in
increased steady-state viral loads as compared to animals
infected with the virus derived from Indian monkeys,
implying that host adaptation plays an important role in
viral fitness and pathogenicity [15].
Taken together, these findings suggest that the efforts to
develop an AIDS vaccine may be well served by examining
a diverse range of antiviral responses and disease suscepti-
bilities in different animal models. Pig-tailed macaques
are of particular interest for several reasons. First, despite
sharing a common ancestor, pig-tailed macaques are
more distantly related to cynomolgus and rhesus
macaques than the latter species are to each other [16,17].
This evolutionary distance may have genetic implications
affecting components of the adaptive immune response,
including T-cell receptor diversity and major histocom-
patibility complex (MHC) molecules [18,19]. Second,
pig-tailed macaques are defective in a restriction factor
TRIM5α [20] used by rhesus macaques to inhibit replica-
tion by certain retroviruses, such as HIV-1 [21]. Pig-tailed
macaques have previously been shown to be susceptible
to infection by HIV-1 [22,23] and recently, by simian-
tropic (st)HIV-1 strains [24]. Third, evidence exists indi-
cating that pig-tails are more susceptible to lentivirus-
induced disease. In a comparative study of pig-tailed and
rhesus macaques infected with SHIVSF162P4, Polacino et al.
found higher peak and setpoint viral loads in pig-tailed
macaques despite similar infectivity between the two spe-
cies, demonstrating that pig-tails were less able to control
infection [25]. This finding was consistent with an early
report by Rosenberg et al., who found that SIVPBj-14-
infected pig-tailed macaques were more susceptible to
death resulting from gastrointestinal distress than their
rhesus counterparts [26]. Similarly, other studies have
documented persistent infection, CD4+ T cell depletion,
and/or development of AIDS-like diseases in pig-tails, but
not rhesus, infected with HIV-2 primary isolates [27-29].
Thus, based on their increased susceptibility to HIV infec-
tion and to lentivirus-induced disease, compared to rhe-
sus, pig-tailed macaques may be a useful animal model
for addressing the diverse responses to HIV-1 infection in
humans.
Elucidation of the immunopathogenic events in mucosa-
associated lymphoid tissue (MALT) has been a major
advance in AIDS research in the last ten years [30,31]. Dra-
matic and irreversible depletion of CD4+ T cells at multi-
ple mucosal sites occurs early after SIV infection [32-42].
Furthermore, the virus specifically targets CCR5+ and acti-
vated memory CD4+ T-cells [35,37,40-45] comprising the
majority of total lymphocytes found in MALT, especially
in the intestine, the largest immunologic organ in the
body [46,47]. In contrast, these subsets represent small
numbers of circulating CD4+  lymphocytes in blood,
lymph nodes, and other secondary lymphoid tissues.
Consequently, depletion of CD4+ T cells in these tissues is
not as dramatic as in the mucosal compartment during
acute infection [32,35,37-39,42,48]. Thus, monitoring
mucosal CD4+ T cells may provide important insight into
lentivirus-induced immunopathogenesis. However, com-
pared to the extensive knowledge accumulated from rhe-
sus studies, less is known about mucosal pathogenic
events in pig-tailed macaques during early infection.
The rapid depletion of CD4+ T cells observed in the MALT
of SIV-infected macaques contrasts with the depletion
observed in peripheral blood of macaques infected with
the first-generation of SHIVs, such as SHIV-HXBc2 and
SHIV89.6P. This discrepancy most likely reflects the
CXCR4-tropism of these SHIVs vs. the CCR5-tropism of
SIV [49,50]. As most of the transmitted viruses in sexual
and maternal-infant HIV-1 infection are CCR5-tropic, theRetrovirology 2009, 6:65 http://www.retrovirology.com/content/6/1/65
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use of R5 SHIVs may be more biologically relevant in pre-
clinical vaccine studies [51]. Furthermore, currently avail-
able SHIVs are predominantly derived from subtype B
isolates of HIV-1 [52-57], whereas the majority of global
infections results from subtype C virus transmission [51].
Recently, Song et al. reported the construction of a CCR5-
tropic subtype C SHIV-1157ipd3N4 (also referred to as
SHIV-C for short), which has been shown to be highly
replication-competent and mucosally transmissible in
Indian- and Chinese-origin rhesus macaques [58]. Three
of five rhesus infected with parental versions of SHIV-
1157ipd3N4 progressed to AIDS within 2–5 years postex-
posure [59]. Two of the 13 rhesus monkeys infected with
SHIV-1157ipd3N4 also progressed to AIDS within 80–
100 weeks (Chenine et al., unpublished data). This path-
ogenic R5-tropic SHIV-C may therefore represent an
important tool for pathogenesis study of primate lentivi-
ruses and preclinical evaluation of candidate HIV vac-
cines. In the present study, we evaluated the infectivity
and pathogenicity of SHIV-1157ipd3N4 in pig-tailed
macaques to determine its potential role as an alternative
challenge model in future AIDS vaccine studies.
Results and discussion
SHIV-1157ipd3N4 infection in pig-tailed macaques
All four pig-tailed macaques inoculated intrarectally with
SHIV-1157ipd3N4 were susceptible to infection and
showed peak plasma viral loads averaging 7.6 ± 5.8 × 106
viral RNA copies/ml by 2 weeks post-inoculation (p.i.)
(Fig. 1A). At this time, macaque M04123 died due to com-
plications of the intestinal biopsy procedure. Its terminal
plasma viral load was 1.1 × 107 copies/ml. Plasma viremia
persisted in two of the three remaining animals, with lev-
els ranging from 7 × 103 to 2 × 105 copies/ml of plasma.
In contrast, virus replication was controlled below the
level of quantification (100 copies/ml) in macaque
J02185 by week 6 following inoculation. Similar kinetics
of infectivity were observed in peripheral blood and
mucosal mononuclear cells (PBMC and MMC), where
mean viral loads peaked by 1.5–2 weeks p.i. (1.5 ± 0.6 ×
103 and 0.3 ± 0.2 × 103 copies/μg of DNA, respectively;
Fig. 1B–C). After the initial peak of viremia, viral load in
PBMC persisted in all three macaques within a range of 21
to 915 copies/μg of DNA (Fig. 1B). In the duodenum,
viral load in MMC was below detection by week 6 p.i.,
except in macaque K03135 that showed elevated levels of
virus between weeks 10 and 16 p.i. (Fig. 1C).
The fact that all four pig-tailed macaques became infected
after inoculation with SHIV-1157ipd3N4 confirmed the
susceptibility of this species to infection by this virus,
which was propagated and studied only in rhesus mon-
keys [58]. Peak viral loads from the four infected pig-
tailed macaques approached the lower range reported for
Indian rhesus, and within the range for Chinese rhesus
[58] (Fig. 1A). Plasma virus also peaked at the same time
in both species (2 weeks p.i.). Viremia persisted in 2/3 pig-
tails during the year-long study, similar to results reported
for rhesus monkeys (3/5 and 3/8, respectively, for Chinese
and Indian rhesus) [58] (Fig. 1A).
Early and severe SHIV-1157ipd3N4-induced mucosal 
immunopathogenesis
To examine the effect of R5 SHIV-C infection on mucosal
CD4+ T cells, especially during the early stages after virus
inoculation, we performed a longitudinal analysis of
CD3+CD4+ T lymphocytes by flow cytometry. As early as 2
weeks p.i., CD3+CD4+ T cells in the duodenum had signif-
icantly decreased from a pre-inoculation level of 38.3% to
13.3% (standard deviation of 5.2% and 15%, respec-
tively) (Fig. 2A). By 3–4 weeks p.i., only 2.2 ± 1% of
CD3+CD4+ T lymphocytes were detectable in the duode-
num of three animals, reflecting a dramatic depletion of
92–97% of the total CD4+ T-cell population in the duode-
nal mucosa. Notably, despite the nearly undetectable
plasma and MMC viral load in macaque J01285 by 6
weeks p.i., the ability to control virus replication did not
appear to lessen the depletion of intestinal CD4+ T cells in
this animal (Fig. 1A and 1C; and Fig. 2A). In fact, J02185
showed the highest degree of CD4+ T-cell depletion in the
duodenum at 97% by 4 weeks p.i. For all three animals,
the percentages of CD3+CD4+ T cells in the duodenum
slightly recovered over the course of 24 weeks to levels
that did not exceed 11.3 ± 2.5%, or approximately 28% of
pre-inoculation levels (Fig. 2A).
The severe loss of CD3+CD4+ T cells was also found in
other mucosal tissues, including the colon and the lung,
the latter accessible by bronchoalveolar lavage (BAL) sam-
pling (Fig. 2B). Similar to the duodenum, depletion of
CD4+ T cells was not observed in the colon at week 1 p.i.
in two macaques (data not shown). By week 4 p.i., CD4+
T-cell levels had decreased from 43.4% to 9.2%, or 79%
from pre-existing levels in macaque L03165. The elimina-
tion of CD4+ T lymphocytes was more severe and rapid in
lung mucosa, where CD3+CD4+ T cells were undetectable
by 3 days p.i. In fact, BAL CD4+ T cells remained at unde-
tectable or nearly undetectable levels for 1–2 weeks after
virus inoculation in two macaques (Fig. 2B; and data not
shown). However, in at least one macaque (L03165), the
percentage of CD3+CD4+ T cells in the BAL returned to
pre-inoculation levels by week 20 p.i. (Fig. 2B).
As a result of the profound depletion of CD4+ T cells in the
mucosal tissues, we observed a striking decrease of
CD4:CD8 T cell ratios during acute infection (Fig. 2C). By
2–4 weeks p.i., the T-cell ratios in the duodenum had
decreased nearly 23-fold, from a pre-inoculation range of
0.47–0.74 to a post-inoculation range of 0.016–0.037.
The decrease in the duodenal T-cell ratios largely persistedRetrovirology 2009, 6:65 http://www.retrovirology.com/content/6/1/65
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Plasma and cell-associated viral loads in pig-tailed macaques infected with SHIV-1157ipd3N4 Figure 1
Plasma and cell-associated viral loads in pig-tailed macaques infected with SHIV-1157ipd3N4. Viral RNA loads 
were measured in plasma (A), and proviral cDNA loads in total mononuclear cells isolated from peripheral blood (B) and duo-
denum (C). To distinguish data points in the early stages of infection, a scale break (//) corresponding to week 8 after inocula-
tion was inserted into the x-axis (same for subsequent figures).
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Mucosal CD4+ T-cell depletion due to SHIV-1157ipd3N4 infection Figure 2
Mucosal CD4+ T-cell depletion due to SHIV-1157ipd3N4 infection. (A) Total lymphocytes isolated from duodenal 
biopsies from infected pig-tailed macaques were analyzed by flow cytometry for CD3+CD4+ T cells. CD4+ T-cell percentages 
were obtained by gating on CD3+ T cells and then lymphocytes. (B) Histogram plots showing a comparison of CD4+ T-cell per-
centages in mucosal tissues of macaque L03165. Duodenal and colonic biopsies, and BAL samples, were taken concurrently at 
the specified timepoints pre- and post-inoculation. (C) CD4:CD8 ratios in the duodenum were generated by using the percent-
ages of total CD4+ and CD8+ T cells.
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throughout the course of infection, with recovery in
CD3+CD4+  T-cell levels resulting in only minimal
increases in the CD4:CD8 ratios, which did not exceed
0.18. In macaque L03165, the massive elimination of BAL
CD4+ T cells as early as 3 days p.i. resulted in a marked
decrease of CD4:CD8 T-cell ratios up to 2 weeks p.i., drop-
ping from a pre-inoculation ratio of 0.43 to a range of 0–
0.003 after infection (data not shown).
To our knowledge, this is the first report of a prospective
analysis of the immunopathogenesis in multiple mucosal
compartments during infection with a R5 SHIV in pig-
tailed macaques. Chen et al. found that pig-tailed
macaques infected with a R5-tropic clade C SHIVCHN19P4
were significantly depleted of jejunal CD4+ T cells at 2
weeks p.i., with no remarkable change in immune activa-
tion or proliferation of CD4+ gut lymphocytes, as meas-
ured by CD25 and Ki67 staining, respectively [60,61].
Chase et al. reported that ileal CCR5+CD4+ T cells of pig-
tails inoculated with an immunosuppressive viral strain
SIV/ΔB670 together with a macrophage-tropic molecular
clone SIV/17E-Fr dropped from average uninfected levels
of 44% to 8% by 2 weeks p.i. [62]. A significant decrease
in CD25hi cells and an increase in Ki67+ cells were also
observed in CD4+ gut lymphocytes from the SIV-infected
animals [62]. Our data confirm and extend these previous
findings that gut immunopathogenesis is a hallmark of
early R5-tropic SIV/SHIV infection in pig-tailed macaques.
The results reported here also indicate that R5 SHIV-C-
induced mucosal pathogenesis in pig-tails followed a sim-
ilar course as described in SIV-infected rhesus. These stud-
ies demonstrated profound CD4+  T-cell losses, nearly
complete in some cases, by days 10–21 after infection [32-
42]. There is no discernable difference in the depletion of
CD4+ T lymphocytes within intestinal and lung mucosa in
pig-tails, with regard to the kinetics or severity of the
depletion, compared to these previous reports in rhesus.
Notably, the elimination of mucosal CD4+ T cells in pig-
tailed macaques was often followed by the partial or lim-
ited return of these populations over the course of the
study period (Fig. 2A–B). In fact, the partial recovery of
CD4+ T cells in the gut of SIVmac251-infected rhesus
macaques has been documented by Veazey et al., who
showed intestinal CD3+CD4+ T cells increased up to 20%
by week 5 p.i. in a few infected animals [40]. Similarly,
Okoye et al. reported that BAL CD4+ T-cell levels from
SIVmac239-infected rhesus initially recovered after early
depletion up to approximately 14 weeks p.i., then
decreased progressively thereafter [63]. The mechanism
underlying the recovery of mucosal CD4+ T cells after
acute infection remains to be defined, although there is
evidence identifying the majority of repopulating intesti-
nal CD4+ T cells as naïve [40,42]. While the rebound of
mucosal CD4+ T cells appeared to be partial and/or tran-
sient, depletion of this cell population in early SHIV infec-
tion was sustained during the course of infection (Fig. 2A–
B). Moreover, peak infection of intestinal mononuclear
cells at 1.5–2 weeks p.i. coincided with the onset of CD4+
T-cell depletion, consistent with previous findings
[33,35,38,39,44,46,61,64,65] (Figs. 1C and 2A). Thus, the
availability of target cells is a critical determinant of
mucosal immunopathogenesis.
Acute SHIV-1157ipd3N4 infection results in specific 
elimination of mucosal CCR5+ and effector memory CD4+ 
T lymphocytes
The selective targeting of CCR5+ and effector memory
CD4+ T cells in the mucosal compartment has been well
documented in SIV-infected rhesus macaques [35,37,40-
45], yet less is known about these subsets in pig-tailed
macaques during infection. We therefore examined
mucosal CD4+ T cells for CCR5 and effector memory
markers. By 2–3 weeks p.i., we found that a large decrease
of duodenal CD4+CCR5+ T cells had occurred in all four
SHIV-1157ipd3N4-infected pig-tailed macaques. Percent-
ages of CCR5-expressing T cells dropped from 79% in
uninfected animals to 13% by 2–3 weeks p.i. (standard
deviation of 9% and 10.5%, respectively), or approxi-
mately a decrease of 82 ± 15.8% from pre-inoculation lev-
els (Fig. 3A). After the initial early depletion, the
percentages of CD4+CCR5+  T cells in three macaques
showed fluctuations before increasing during the later
stages of the study period. By 20–24 weeks p.i., the per-
centages of CD4+CCR5+ T cells had recovered to 98 ± 26%
of pre-inoculation numbers (Fig. 3A). It is unknown
whether this level of recovery was transient, based on a
singular measurement after week 12, or influenced by the
small CD4+ T-cell population remaining (8.8 ± 4.2%) at
20–24 weeks p.i. Yet, the fact that this increase occurred in
all three animals indicates the recovery of CD4+CCR5+ T
cells during this time was consistent (Fig. 3A).
A substantial reduction of CD4+ effector memory T cells
(TEM), identified by their CD28-CD95+ phenotype, was
also seen in the duodenum of all four infected pig-tails. By
2–4 weeks p.i., these numbers fell from 33.2% to 0% in
J02185; 75.6% to 3.6% in K03135; 22.2% to 8.6% in
L03165; and 21.9% to 7.4% in M04123 (Fig. 3B). On
average, CD4+ TEM dropped from 38.2% to 4.9% (stand-
ard deviation of 25.5% and 3.9%, respectively), reflecting
an 80.7 ± 19.7% decrease of pre-existing populations.
CD4+ TEM cells were undetectable by flow cytometry at 2
weeks p.i. in macaque J02185, the same animal whose
CD4+ T cells were 97% depleted by week 4 p.i. (Figs. 2A
and 3B). By 20–24 weeks p.i., the numbers of CD4+ TEM in
all three macaques followed beyond the acute phase had
recovered to 62.4 ± 11.3% of their pre-inoculation levels,
despite only a 28% recovery in total CD4+ T cells (Figs. 2A
and 3B). The coincident increase of central memory CD4+Retrovirology 2009, 6:65 http://www.retrovirology.com/content/6/1/65
Page 7 of 16
(page number not for citation purposes)
Selective loss of intestinal CCR5+ and effector memory CD4+ T cells during early R5 SHIV-C infection Figure 3
Selective loss of intestinal CCR5+ and effector memory CD4+ T cells during early R5 SHIV-C infection. Total 
lymphocytes isolated from duodenal biopsies from SHIV-1157ipd3N4-infected pig-tailed macaques were analyzed by flow 
cytometry for CD4+ T-cell subsets based on expression of (A) CCR5+ (B) CD28-CD95+ (TEM) and (C) CD28+CD95+ (TCM). 
Percentages of subsets were obtained by gating on CD3+ T cells, lymphocytes, and then CD4+ T cells.
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T cells (TCM) beginning at 2 weeks p.i., when the effector
memory subset was profoundly depleted (Fig. 3C), sug-
gests a homeostatic mechanism whereby the TEM  are
derived from the proliferation and differentiation of the
TCM population [63]. Thereafter, TCM levels reached a pla-
teau in all three animals until week 12 p.i., at which time
this cell population decreased in K03135.
Our results indicate that SHIV-1157ipd3N4 induced a
similar immunopathogenesis in pig-tails as SIV in rhesus,
based on the R5-tropism of both viruses. Rhesus
macaques showed a dramatic decline of mucosal CD4+ T
cells with a CCR5+ memory phenotype at 11–28 days fol-
lowing infection [35,37,40-45] The specific targeting of
mucosal CCR5 and effector memory CD4+ T cell subsets is
consistent with the elevated levels of CCR5 on activated
memory T cells [32,46,47], and the predominance of an
activated/memory phenotype in mucosal tissue [30,31].
In fact, rhesus studies have reported that large numbers of
CCR5+ target cells reside at mucosal sites, including the
gut and lung, where approximately 50–90% of CD4+ T
cells express CCR5 [30-32,35,40,41,44,66]. We found
comparable levels of CCR5+CD4+ T cells in our analysis of
mucosal tissues from uninfected pig-tailed macaques,
including the duodenum (79 ± 9%), colon (63 ± 10%),
and BAL (98 ± 0.4%), the latter reported for two of four
animals. Therefore, as reported in SIV-infected rhesus, the
mucosa provides a critical reservoir of CD4+ target cells for
R5-specific SHIV-C infection in pig-tails as demonstrated
by the sharp decrease of CCR5+ and TEM cells by 2 weeks
p.i (Fig. 3A–B).
The basis for the apparent increase of intestinal CCR5+
and TEM cells after initial depletion (Fig. 3A–B) is not well
understood. As the percentages of the subsets are based on
total CD4+  T numbers, it follows that proportional
increases in CCR5+ and TEM cells concurrent with severe
CD4+ T-cell losses during acute and chronic infection (Fig.
2A) may result in the apparent "recovery" of the subset
populations [42]. Further, Veazey et al. observed at 2
weeks p.i. that more than 50% of the residual intestinal
CD4+ T cells in a few SIV-infected rhesus were CCR5+ and
naive (CD45RAHI) [40]. At 4–6 months p.i. most residual
CD4+ T cells in the gut were naïve, but lacked CCR5
expression [40]. Thus, while it is possible that the "recov-
ery" of CCR5+ and memory subsets may represent actual
residual cells which remained and expanded, these popu-
lations may also be derived from naive cells newly formed
and recruited to the mucosa early after infection [40,42].
Loss of specific CD4+ T cell subsets during acute SHIV-
1157ipd3N4 infection also occurs in peripheral blood
A comparatively smaller, but detectable, decrease in the
absolute number of CD3+CD4+ T-cells was also observed
in peripheral blood at early timepoints following virus
inoculation, dropping 12 ± 29% and 44 ± 19% from pre-
existing levels, at 2 and 4 weeks p.i., respectively (Fig. 4A).
Thereafter, absolute peripheral CD4+  T-cell counts
remained relatively stable in two of three animals, ranging
from 519 to 1,257 cells/μl for the duration of the study
period. CD4+ T cell numbers dropped below 200 cells/μl
in macaque K03135 at week 20 p.i. and have since shown
a progressive decline at all subsequent timepoints, indi-
cating progression to AIDS. Between weeks 10–16 p.i.,
animal K03135 showed a pronounced increase in viral
load in the duodenum (Fig. 1C). The basis for this
increase is not clear, but may reflect immune escape or
local reactivation of latent viruses [67-69]. There were also
no overt clinical signs that correlated with this distinct
viral peak. However, it is notable that this increase in
MMC viral load occurred at the same time as the increase
in plasma viral load (Fig. 1A), and just before the decline
of CD4+ T-cells in peripheral blood (Fig. 4A).
We also observed decreases in the absolute counts of
CCR5+  and CD28-CD95+  subsets in peripheral blood
CD4+ T cells from all four pig-tailed macaques in early R5
SHIV-C infection (Fig. 4B–C). By 2–3 weeks p.i., CCR5-
expressing T cells dropped from 15.2 to 6.2 cells/μl
(standard deviation of 4.1 and 2.3 cells/μl, respectively),
or 56.9 ± 21.6% from pre-challenge levels (Fig. 4B). Sim-
ilarly, CD4+ TEM fell from 32.9 to 13.1 cells/μl (standard
deviation of 12.5 and 4.4 cells/μl, respectively), reflecting
a loss of 58 ± 13.7% in this population (Fig. 4C). How-
ever, compared to the duodenum, substantially lower lev-
els of these subsets were found in the peripheral blood of
uninfected pig-tails (for CCR5+, 79 ± 9% vs. 2.8 ± 0.3%;
for CD28-CD95+, 38.2 ± 25.5% vs. 4.5 ± 1.7%) (Fig. 3A–
B; and data not shown). Similarly low levels of peripheral
blood CD4+ T cells expressing CCR5 and having an effec-
tor memory phenotype (approximately 3–16%) have
been reported in rhesus macaques [30,31,35,40,41,66].
Thus, consistent with previous findings in rhesus, the
small numbers of pre-existing peripheral CCR5+ and TEM
cells in pig-tailed macaques precluded dramatic changes
to the total absolute CD4+ T-cell count, despite substantial
losses to the population subsets due to SHIV-C infection
(Fig. 4).
Macaque L03165 died under anesthesia during a mucosal
sampling procedure at 48 weeks p.i. This animal had
shown persistent viremia, but otherwise normal periph-
eral CD4+  T-cell levels (Figs. 1A and 4A). Necropsy
revealed a near-occlusive pulmonary arterial thrombus.
The clinical history of L03165 indicated a dramatically
reduced platelet count and a moderate decrease in the
albumin:globulin protein ratio (Fig. 5A–B). A reduced
platelet count has also been documented in macaque
K03135, the only animal to have developed peripheral
CD4+ T-cell lymphopenia (Fig. 4A; and Fig. 5A and 5C).Retrovirology 2009, 6:65 http://www.retrovirology.com/content/6/1/65
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Selective loss of CD4+ T-cell subsets in the peripheral blood of R5 SHIV-C-infected pig-tailed macaques Figure 4
Selective loss of CD4+ T-cell subsets in the peripheral blood of R5 SHIV-C-infected pig-tailed macaques. Flow 
cytometric evaluation of (A) total CD4+ T cells and subsets based on expression of (B) CCR5+ and (C) CD28-CD95+ (TEM) was 
done using whole blood (for total CD4+ T cells) or total lymphocytes isolated from peripheral blood (for subsets). Analysis was 
performed by gating first on lymphocytes and then CD3+CD4+ T cells. Total absolute counts of CD4+ T cells were calculated 
by multiplying the percentage of CD3+CD4+ T cells by the number of total lymphocytes/ml from complete blood count (CBC) 
analysis. Further multiplication of the percentage of cells expressing CCR5+ or CD28-CD95+ was done to calculate the abso-
lute counts of the subsets. The dashed line in (A) indicates 200 cells/μl, the threshold level defining human AIDS.
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Findings reported here demonstrate the pathogenic
potential of SHIV-1157ipd3N4 infection in pig-tailed
macaques. The differential clinical responses in J02185,
K03135, and L03165 (Figs. 1A, C, and 4A) suggest a spec-
trum of disease courses is possible from SHIV-C infec-
tions, consistent with previous findings in SIV and R5
SHIV strains, and the outbred nature of the animals stud-
ied. Peripheral lymphopenia and AIDS-defining events
have also been documented in an Indian rhesus infected
with SHIV-1157ipd, a late-stage biological isolate from
which SHIV-1157ipd3N4 was directly derived [58,59].
Additionally, long-term monitoring of SHIV-1157ipd3N4
infection in rhesus has shown AIDS progression in two
animals (Chenine et al., unpublished data). Song et al.
reported relatively stable absolute peripheral CD4+ T-cell
counts in all Indian- and Chinese-origin rhesus acutely
infected with SHIV-1157ipd3N4 and followed for 12
weeks [58]. They also found that 43–66% of peripheral
Thrombocytopenia and hematological changes in SHIV-C-infected pig-tailed macaques Figure 5
Thrombocytopenia and hematological changes in SHIV-C-infected pig-tailed macaques. Blood samples were col-
lected at the indicated times following SHIV-C inoculation and analyzed for (A) platelet counts, (B) albumin:globulin ratios, and 
(C) correlation between platelet and peripheral CD4+ T-cell counts. Note the different scales along the x- and y-axes in (C). 
Spearman's correlation coefficient and statistical significance (r- and p-values, respectively) were calculated with Prizm 4 
(GraphPad Software, Inc).
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CD4+ TCM was depleted in two of five Indian rhesus at 8
weeks p.i. Compared to pre-existing levels at week 0, we
found a similar 39–59% decrease of peripheral CD4+ TCM
in pig-tails at 2 weeks p.i.; by 8 weeks p.i., this decrease
was 5–28%, reflecting the partial recovery of these cells in
blood (data not shown). Interestingly, we observed an
association between low pre-inoculation counts of
peripheral CD4+ TCM and progression to SHIV-C-induced
disease in one animal (K03135) (data not shown), con-
sistent with previous findings in SIVmac251-infected pig-
tailed macaques [70]. Rhesus monkeys infected with
another pathogenic R5 SHIV-C, SHIV-2873Nip, which
was constructed from the backbone of SHIV-1157ipd3N4,
also demonstrated a loss of peripheral CD4+ memory T
cells, along with depletion of gut CD4+ T lymphocytes
[71].
Antibody-mediated immune responses to SHIV-
1157ipd3N4 infection
All three animals that were followed beyond the acute
phase of SHIV-1157ipd3N4 infection were monitored for
their antigen-specific antibody responses. As shown in
Fig. 6, SIV-specific (Fig. 6A) and HIV-1 gp120-specific
antibodies (Fig. 6B) were detected as early as 4 wk p.i. The
antibody titers continued to increase for the following 6–
8 months and persisted throughout the study period of a
year, including animal K03135 that showed significant
peripheral blood CD4+ T-cell depletion after wk 24 p.i.
(Fig. 4A), as well as animal J02185 that controlled virus
replication after the acute phase and showed the lowest
antibody response (Fig. 1A).
Neutralizing antibody (NtAb) activity was determined by
the pseudotyped virus assay in TZM-bl cells [72]. Cross-
clade NtAb responses were detected as early as 24 weeks
p.i. (data not shown) against both subtype A and B pri-
mary isolates (Table 1), consistent with a previous report
of rhesus monkeys infected with SHIV-1157ip, the paren-
tal virus of SHIV-1157ipd3N4 [73]. Similar to antibody
responses measured by ELISA, animals with high and per-
sistent viral loads (K03135 and L03165) showed greater
levels of NtAb activities, consistent with the role of anti-
gen load driving antibody responses. It should be noted
however that the neutralizing activities observed were
effective only against primary viruses that were relatively
easy to neutralize (Q461d1, SF162, and SS1196.1). No
activity was detected against 89.6 and two viruses repre-
sented in the standard subtype B primary isolate panel
(QH0692.42 and SC422661.8) [74]. No neutralization
was observed against the homologous virus (data not
shown) or a heterologous subtype C virus 1084i [75]
(Table 1). This was in contrast to the high-titered neutral-
izing activity against both homologous and heterologous
R5 SHIV-C isolates in rhesus macaques infected with the
parental virus SHIV-1157ip [73]. Thus, the NtAb profile in
SHIV-1157ipd3N4-infected pig-tailed macaques does not
conform to the paradigm that homologous NtAbs arise
before cross-clade NtAbs. In fact, cross-subtype NtAbs at
titers similar to that in pooled plasma from subtype C-
infected humans were observed in K03165 and L03165
relatively early after infection (wk 24, data not shown; and
Table 1). The basis for this difference in NtAb responses is
not known; but, it is likely to be due to the accessibility of
conserved NtAb targets in certain isolates, regardless of
their subtype classifications [76].
Conclusion
Our prospective analysis of SHIV-1157idp3N4-infected
animals with emphasis on early acute infection demon-
strates that R5 SHIV-C-induced pathogenesis in pig-tailed
macaques parallel findings in CCR5-tropic SIV/SHIV rhe-
sus models. Findings reported here support the value of
pig-tailed macaques as a relevant animal model for the
study of lentiviral pathogenesis and preclinical AIDS vac-
cines.
Methods
Animals
Four juvenile pig-tailed macaques (M. nemestrina), all
negative for simian type D retrovirus by serology and
polymerase chain reaction (PCR), were used in this study.
Animals were inoculated intrarectally, and tissue samples
were collected at specific timepoints pre- and post-inocu-
lation for prospective monitoring of viral loads, T-cell
subsets, blood chemistry, and antibody responses. Gen-
eral health of the animals, including body weight and
temperature, was monitored by routine examinations. All
animals were cared for in accordance with established
National Institutes of Health guidelines, and the experi-
mental procedures were performed with the approval of
the Institutional Animal Care and Use Committee at the
University of Washington.
Virus stock
The derivation of SHIV-1157ipd3N4 was described by
Song et al. [58]. A rhesus PBMC-grown stock was used for
this study. All animals received 1 ml of undiluted SHIV-
1157ipd3N4 by an atraumatic intrarectal inoculation. The
virus stock had a p27 concentration of 95 ng/ml and an in
vitro infectivity as determined by 50% tissue culture infec-
tious doses (TCID50) of 106 per ml as titrated in TZM-bl
cells (R. Song, personal communication).
Cell line
TZM-bl cells (also called JC53-bl, clone 13) were contrib-
uted by John Kappes and Xiaoyun Wu and obtained from
the National Institutes of Health (NIH) AIDS Reference
Reagent Repository Program (catalog no. 8129) [77].
Cells were cultured in Dulbecco modified Eagle mediumRetrovirology 2009, 6:65 http://www.retrovirology.com/content/6/1/65
Page 12 of 16
(page number not for citation purposes)
supplemented with 10% fetal bovine serum (FBS) and 2
mM glutamine.
Tissue collection and isolation of lymphocytes
Peripheral blood was drawn by venipuncture into EDTA
or SST tubes for extraction of plasma and PBMC, or serum,
respectively. BAL samples were obtained by laryngoscope-
aided introduction of a 5 mm video bronchoscope
through the mouth and into the trachea. Lavage with 3–5
separate 10-ml aliquots of sterile saline was performed by
injecting the saline into a terminal bronchiole, after which
the saline infusate was aspirated with continuous flow
vacuum at approximately 90–100 mm Hg of negative
pressure. For endoscope-guided pinch biopsies obtained
from the duodenum or colon, an 8.9 mm diameter video
gastroscope (Karl Storz Veterinary Endoscopy, Goleta,
CA) was inserted as far as the distal duodenum/proximal
jejunum (90–130 cm from the mouth), or into the
descending/transverse colon (50–70 cm from the anus),
respectively. A maximum of 23 pinch biopsies (about 1
mm3) was collected via the gastroscope with sterile 2.0
mm biopsy forceps.
EDTA-treated blood was subjected to Lymphoprep
(Ficoll) density gradient centrifugation for isolation of
viable PBMC, or stained by a whole blood lysis technique
as described below. BAL samples were centrifuged to pel-
let cells, but enrichment of lymphocytes was not per-
formed. Biopsies were pooled from the duodenum or
colon, treated with 5 mM EDTA and 60 U/ml collagenase,
and isolated cells were enriched for lymphocytes by Per-
coll density gradient centrifugation, as previously
described [40,42]. Viability of intestinal lymphocytes
averaged 88 ± 4%, as determined by trypan blue exclu-
sion.
Plasma and cell-associated viral loads
Viral load was assayed as previously described [72,78].
Briefly, viral RNA load in EDTA-anticoagulated, cell-free
plasma was determined by real-time RT-PCR after reverse
transcriptase reaction. Proviral cDNA load in total mono-
nuclear cells from peripheral blood or duodenal biopsies
was determined by real-time PCR analysis.
Lymphocyte immunophenotyping
Cells were stained for four-color flow cytometric analysis,
using antibodies directly conjugated to either fluorescein
isothiocyanate (FITC), phycoerythrin (PE), peridinin
chlorophyll protein (PerCP), or allophycocyanin (APC).
Briefly, for whole blood staining, 1 ml of whole blood was
treated with 14 ml of ammonium chloride lysis solution
for 7 min, centrifuged (700 × g, 5 min), and the resultant
cell pellet was resuspended in 1 ml of staining medium
(RPMI supplemented with 1% FBS and 0.02% NaN3)
[72]. Fifty-μl aliquots of the cell suspension were triple-
stained with CD3-FITC (SP34-2), CD4-PerCP-Cy5.5
(L200), and CD8-APC (SK1), and double-stained with
CD2-FITC (S5.2) and CD20-PerCP-Cy5.5 (L27). Cells
were incubated in the dark for 20 to 30 min, washed, and
resuspended in 1% paraformaldehyde. For mucosal and
peripheral blood lymphocytes, cells were stained by incu-
bating 1–5 × 105 cells with combinations of monoclonal
antibodies at 4°C for 30 min, washed, and then fixed in
2% paraformaldehyde. Monoclonal antibodies used were:
CD3-FITC (SP34), CD3-PerCP (SP34-2), CD4-APC
(L200), CD8-PerCP (SK1), CD8-APC (SK1), CCR5-PE
(3A9), CD28-PE (CD28.2), and CD95-FITC (DX2). All
antibodies were purchased from Becton Dickinson Bio-
sciences (San Jose, CA). Controls included appropriate
unstained, fluorescence-minus-one (FMO)-stained, and
single-color-stained, samples, for compensation and gat-
Virus-specific antibody responses in pig-tailed macaques  infected with SHIV-1157ipd3N4 Figure 6
Virus-specific antibody responses in pig-tailed 
macaques infected with SHIV-1157ipd3N4. Macaque 
sera were collected at the indicated times following SHIV-C 
inoculation and analyzed by ELISA for antibody responses 
directed against SIVmac whole virus (A) or HIV-1SF162 gp120 
(B). Endpoint titers were defined as the reciprocal of the 
highest dilution that gave an optical absorbance value at least 
threefold higher than the average values obtained with SIV-
negative macaque sera.
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ing. Data were acquired on a FACSCalibur flow cytometer
(Becton Dickinson Immunocytometry Systems), where
10,000–20,000 gated lymphocyte events were collected,
and analyzed with FlowJo software (Version 7.1.3, Tree
Star, Ashland, OR). The absolute numbers of CD3+CD4+
lymphocytes were determined using flow cytometry anal-
ysis software according to guidelines from the Centers for
Disease Control and Prevention for T-cell determinations
in HIV-infected individuals [72].
Enzyme-linked immunosorbent assay (ELISA)
The titers of whole virus SIVmac- and HIV-1SF162 gp120-
specific antibodies were measured by ELISA as previously
described [79]. Endpoint titers were determined as the
reciprocal of the highest serum dilution that resulted in an
optical density reading greater than the average values
obtained with negative macaque sera plus three standard
deviations.
Neutralization assay
The neutralization activity of sera from SHIV-
1157ipd3N4-inoculated pig-tailed macaques was meas-
ured in a pseudotyped virus assay as described [72]. Indi-
cator viruses with envelope derived from the following
HIV-1 were used: subtype A isolate Q461d1 [80]; subtype
B isolates SF162, SS1196.1, 89.6, QH0692.42, and
SC422661.8 [72,74]; and subtype C isolate 1084i [75]. All
assay stocks were titrated in TZM-bl cells as described pre-
viously [72,74]. Indicator virus containing 150 TCID50
was incubated with serial dilutions of serum samples
(starting at 1:30) in triplicate in a total volume of 60 μl for
1.5 hr at 37°C in 96-well U-bottom tissue culture plates
(Corning). TZM-bl cells plated 24 hr previously (3,000
cells in 100 μl of growth medium) were treated with 2 μg/
ml polybrene for 30 min at 37°C. One set of control wells
received cells plus virus (virus control), and another set
received cells only (background control). After a 72-hr
incubation, luciferase activities were analyzed using
BrightGlo substrate solution as described by the supplier
(Promega). Neutralization activity was expressed as the
highest serum dilution that resulted in 50% reduction of
relative luciferase units (RLU). Values obtained with pre-
inoculation sera were subtracted from those obtained
with post-inoculation sera for each animal.
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